Table 3.
Univariate analysis of variables associated with TTF and OS
| TTF | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Median, y | HR | 95% CI | P | Median, y | HR | 95% CI | P | |
| Median age, y | ||||||||
| >68 | 2.00 | 1.48 | 0.85-2.59 | .17 | 2.90 | 1.94 | 0.96-3.90 | .06 |
| ≤68 | 2.81 | 4.32 | ||||||
| Hb concentration, g/L | ||||||||
| ≥100 | 3.26 | 0.38 | .001 | 4.32 | 0.41 | 0.21-0.83 | .01 | |
| <100 | 1.55 | 0.21-0.69 | 2.75 | |||||
| Median WCC, ×109/L | ||||||||
| >14.6 | 2.85 | 0.55 | 0.32-0.96 | .03 | 4.26 | 0.74 | 0.38-1.43 | .37 |
| ≤14.6 | 1.78 | 3.17 | ||||||
| Median platelet count, ×109/L | ||||||||
| >199 | 2.23 | 0.86 | 0.49-1.50 | .59 | 4.32 | 0.54 | 0.28-1.05 | .07 |
| ≤199 | 2.00 | 2.90 | ||||||
| Median PBB, % | ||||||||
| >1 | 1.55 | 2.10 | 1.20-3.67 | .01 | 2.91 | 2.53 | 1.30-4.94 | .006 |
| ≤1 | 2.76 | 4.32 | ||||||
| Transfusion dependence | ||||||||
| Yes | 1.46 | 2.37 | 1.36-4.12 | .002 | 2.47 | 2.52 | 1.28-4.95 | .007 |
| No | 3.26 | 5.51 | ||||||
| Baseline spleen size, cm | ||||||||
| ≥10 | 2.28 | 0.72 | 0.33-1.55 | .40 | 4.26 | 0.67 | 0.28-1.65 | .39 |
| <10 | 1.71 | 2.37 | ||||||
| JAK inhibitor | ||||||||
| Ruxolitinib | 2.27 | 0.71 | 0.39-1.31 | .27 | 4.26 | 1.23 | 0.60-2.55 | .57 |
| Momelotinib | 1.71 | 4.32 | ||||||
| Diagnosis | ||||||||
| PMF | 1.92 | 0.72 | 0.41-1.25 | .24 | 3.30 | 1.07 | 0.56-2.06 | .84 |
| PPV-/PET-MF | 2.53 | 4.32 | ||||||
| DIPSS | ||||||||
| Low/Intermediate-1 | 4.69 | 1.81 | 0.83-3.96 | .14 | NA | 1.66 | 0.63-4.32 | .30 |
| Intermediate-2 | 2.53 | 3.55 | 1.63-7.73 | .001 | 4.26 | 4.09 | 1.59-10.50 | .004 |
| High | 1.46 | 2.37 | ||||||
| JAK2/MPL (n = 85) | ||||||||
| Yes | 2.23 | 0.75 | 0.40-1.40 | .36 | 4.26 | 0.80 | 0.38-1.71 | .57 |
| No | 1.78 | 2.90 | ||||||
| CALR (n = 14) | ||||||||
| Yes | 1.78 | 0.94 | 0.43-2.10 | .89 | NA | 0.75 | 0.27-2.13 | .59 |
| No | 2.23 | 3.30 | ||||||
| ASXL1 (n = 33) | ||||||||
| Yes | 1.71 | 1.86 | 1.06-3.24 | .03 | 2.37 | 2.27 | 1.17-4.40 | .02 |
| No | 2.76 | 5.51 | ||||||
| SRSF2 (n = 7) | ||||||||
| Yes | 2.52 | 1.00 | 0.40-2.54 | .99 | 2.64 | 1.30 | 0.46-3.70 | .62 |
| No | 2.09 | 4.26 | ||||||
| EZH2 (n = 8) | ||||||||
| Yes | 1.10 | 2.94 | 1.31-6.60 | .009 | 1.83 | 4.17 | 1.69-10.28 | .002 |
| No | 2.28 | 4.32 | ||||||
| IDH1/IDH2 (n = 4) | ||||||||
| Yes | 2.76 | 0.73 | 0.18-3.01 | .67 | 2.90 | 1.34 | 0.32-5.61 | .69 |
| No | 2.09 | 4.26 | ||||||
| TET2 (n = 28) | ||||||||
| Yes | 1.95 | 0.98 | 0.52-1.85 | .95 | 2.45 | 1.57 | 0.77-3.21 | .21 |
| No | 2.28 | 4.32 | ||||||
| U2AF1 (n = 10) | ||||||||
| Yes | 1.95 | 1.60 | 0.68-3.77 | .28 | 2.37 | 1.14 | 0.35-3.76 | .82 |
| No | 2.23 | 4.26 | ||||||
| SF3B1 (n = 13) | ||||||||
| Yes | 1.99 | 1.36 | 0.64-2.91 | .42 | NA | 0.91 | 0.32-2.58 | .86 |
| No | 2.23 | 3.30 | ||||||
| CBL (n = 5) | ||||||||
| Yes | 1.03 | 3.66 | 1.09-12.24 | .04 | 1.20 | 2.92 | 0.69-12.44 | .15 |
| No | 2.28 | 4.26 | ||||||
| DNMT3A (n = 6) | ||||||||
| Yes | 1.13 | 2.06 | 0.74-5.74 | .17 | 2.00 | 2.34 | 0.71-7.72 | .16 |
| No | 2.28 | 4.26 | ||||||
| NRAS (n = 5) | ||||||||
| Yes | 1.38 | 1.57 | 0.57-4.38 | .39 | 4.26 | 1.63 | 0.50-5.35 | .42 |
| No | 2.23 | 4.32 | ||||||
| ASXL1/EZH2 (n = 37) | ||||||||
| Yes | 1.49 | 2.36 | 1.36-4.11 | .002 | 2.37 | 2.90 | 1.48-5.99 | .002 |
| No | 3.26 | 5.51 | ||||||
| HMR profile (n = 43) | ||||||||
| Yes | 1.67 | 2.06 | 1.19-3.58 | .01 | 2.40 | 2.61 | 1.33-5.14 | .005 |
| No | 3.46 | 5.51 | ||||||
| Number of mutations (including driver) | ||||||||
| 1 | NA | 4.32 | ||||||
| 2 | 2.53 | 1.23 | 0.54-2.81 | .63 | NA | 0.99 | 0.37-2.66 | .99 |
| ≥3 | 1.49 | 2.19 | 0.95-5.05 | .07 | 2.37 | 2.65 | 1.04-6.75 | .04 |
| 0-2 mutations | ||||||||
| No HMR | 3.45 | NA | ||||||
| HMR | 1.78 | 1.94 | 0.92-4.08 | .08 | 3.30 | 1.75 | 0.68-4.54 | .25 |
| ≥3 mutations | ||||||||
| No HMR | 2.21 | 1.87 | 0.63-5.52 | .26 | 4.26 | 1.65 | 0.46-5.93 | .45 |
| HMR | 1.49 | 2.50 | 1.30-4.80 | .006 | 2.28 | 4.16 | 1.87-9.27 | .0005 |
NA, event-free rate did not reach 50%.